Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bortezomib, lenalidomide, and dexamethasone in patients with high-risk smoldering myeloma
KCT0006266Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bortezomib, lenalidomide and dexamethasone in smoldering multiple myeloma (SMM), sponsored by Boryung. Started Dec 2021; status: recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on KCT0006266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006266.